

# Genetics And Neural Plasticity After Stroke

Steven C. Cramer, MD

**Professor, Depts. Neurology, Anatomy & Neurobiology, and PM&R  
Clinical Director, Sue & Bill Gross Stem Cell Research Center  
Associate Director, Institute for Clinical & Translational Science**

**University of California, Irvine**

# Disclosures

Dr. Cramer has served as a consultant for MicroTransponder, Dart Neuroscience, and Toyama.

“Genetic variation, stress, and functional outcomes  
after stroke rehabilitation”

R01-NR015591

[stroke@uci.edu](mailto:stroke@uci.edu)

# Genetics And Neural Plasticity After Stroke

Genetic variation

Measures of neural plasticity

Studies of genetic polymorphisms related to stroke recovery

Genetic variation

Measures of neural plasticity

Studies of genetic polymorphisms related to stroke recovery

# Genetics--what are the variables?

---

## Human DNA

23 pairs of chromosomes

~6.3 billion base pairs

~20,000 protein-encoding genes

## Alleles

Different forms of the same gene [*Sickle cell disease*]

Generally, each person has 2 alleles for a given gene

## Classifying genetic variation

---

Genetic mutation: rare, causes signif functional change [*HD*]

Genetic polymorphism: not rare (frequency  $\geq 1\%$ ), relatively small effect on behavior or phenotype [*blood type*]

Many types of polymorphism, e.g., single nucleotide polymorphisms (SNP) [*BDNF val<sup>66</sup>met*], variable number of tandem repeats, insertions/deletions, etc

Numerous classes of genetic variation, e.g., can have translocations of large amounts of DNA, frameshift, copy number variations

Epigenetics: changes in the regulation of gene activity and expression not dependent on primary gene sequence

# Understanding genetic variation via interactions

---

Interaction with another gene

*Epistasis*: when the expression of one gene is modified by another gene



# Understanding genetic variation via interactions

---

Interaction with another gene

*Epistasis*: when the expression of one gene is modified by another gene

Interaction with chemical state

# Understanding genetic variation via interactions

---

Interaction with another gene

*Epistasis*: when the expression of one gene is modified by another gene

Interaction with chemical state

Interaction with experience

## Approaches to studying genetic association

- Candidate gene approach, examine key genes
- Genome-wide association study, assesses massive # polymorphisms
- Gene score, examine group of genes across one system
- Many other possible approaches, e.g., exome sequencing, epigenetics, transcriptomic variation

# Stroke Genetics Network (SiGN)

---

# Stroke Genetics Network (SiGN)

---


## Stroke Genetics Network (SiGN) Study Design and Rationale for a Genome-Wide Association Study of Ischemic Stroke Subtypes

James F. Meschia, MD; Donna K. Arnett, PhD; Hakan Ay, MD; Robert D. Brown Jr, MD;  
Oscar R. Benavente, MD; John W. Cole, MD, MS; Paul I.W. de Bakker, PhD;  
Martin Dichgans, MD; Kimberly F. Doheny, PhD; Myriam Fornage, PhD; Raji P. Grewal, MD;  
Katrina Gwinn, MD; Christina Jern, MD; Jordi Jimenez Conde, MD, PhD;  
Julie A. Johnson, PharmD; Katarina Jood, MD; Cathy C. Laurie, PhD; Jin-Moo Lee, MD, PhD;  
Arne Lindgren, MD; Hugh S. Markus, FRCP; Patrick F. McArdle, PhD;  
Leslie A. McClure, PhD; Braxton D. Mitchell, PhD; Reinhold Schmidt, MD;  
Kathryn M. Rexrode, MD; Stephen S. Rich, PhD; Jonathan Rosand, MD, MSc;  
Peter M. Rothwell, MD; Tatjana Rundek, MD; Ralph L. Sacco, MD; Pankaj Sharma, MD;  
Alan R. Shuldiner, MD; Agnieszka Slowik, MD; Sylvia Wassertheil-Smoller, PhD;  
Cathie Sudlow, MD; Vincent N.S. Thijs, MD; Daniel Woo, MD; Bradford B. Worrall, MD, MSc;  
Ona Wu, PhD; Steven J. Kittner, MD; on behalf of the NINDS SiGN Study

# Stroke Genetics Network (SiGN)

## Stroke Genetics Network (SiGN) Study Design and Rationale for a Genome-Wide Association Study of Ischemic Stroke Subtypes

James F. Meschia, MD; Donna K. Arnett, PhD; Hakan Ay, MD; Robert D. Brown Jr, MD;  
Oscar R. Benavente, MD; John W. Cole, MD, MS; Paul I.W. de Bakker, PhD;  
Martin Dichgans, MD; Kimberly F. Doheny, PhD; Myriam Fornage, PhD; Raji P. Grewal, MD;  
Katrina Gwinn, MD; Christina Jern, MD; Jordi Jimenez Conde, MD, PhD;  
Julie A. Johnson, PharmD; Katarina Jood, MD; Cathy C. Laurie, PhD; Jin-Moo Lee, MD, PhD;  
Arne Lindgren, MD; Hugh S. Markus, FRCP; Patrick F. McArdle, PhD;  
Leslie A. McClure, PhD; Braxton D. Mitchell, PhD; Reinhold Schmidt, MD;  
Kathryn M. Rexrode, MD; Stephen S. Rich, PhD; Jonathan Rosand, MD, MSc;  
Peter M. Rothwell, MD; Tatjana Rundek, MD; Ralph L. Sacco, MD; Pankaj Sharma, MD;  
Alan R. Shuldiner, MD; Agnieszka Slowik, MD; Sylvia Wassertheil-Smoller, PhD;  
Cathie Sudlow, MD; Vincent N.S. Thijs, MD; Daniel Woo, MD; Bradford B. Worrall, MD, MSc;  
Ona Wu, PhD; Steven J. Kittner, MD; on behalf of the NINDS SiGN Study



Genetic variation

Measures of neural plasticity

Studies of genetic polymorphisms related to stroke recovery

# Cellular & molecular events underlying stroke recovery

## Ipsilesional changes

↑ inflammatory markers  
↑ growth-associated proteins  
↑ cell cycle proteins  
↑ growth factors  
GABA receptor downregulation  
↑ NMDA receptor binding  
angiogenesis  
hyperexcitability & facilitation of LTP  
synaptogenesis  
↑ dendrite branching/spine density  
↑ neuronal sprouting  
extracellular matrix remodelling  
↑ cortical thickness

## Contralesional changes

↑ inflammatory markers  
↑ growth-associated proteins  
GABA receptor downregulation  
↑ NMDA receptor binding  
neuronal hyperexcitability  
↑ dendrite br/spine density  
synaptogenesis  
↑ cortical thickness



# Cellular & molecular events underlying stroke recovery

## Ipsilesional changes

- ↑ inflammatory markers
- ↑ growth-associated proteins
- ↑ cell cycle proteins
- ↑ growth factors
- GABA receptor downregulation
- ↑ NMDA receptor binding
- angiogenesis
- hyperexcitability & facilitation of LTP
- synaptogenesis
- ↑ dendrite branching/spine density
- ↑ neuronal sprouting
- extracellular matrix remodelling
- ↑ cortical thickness

## Contralesional changes


- ↑ inflammatory markers
- ↑ growth-associated proteins
- GABA receptor downregulation
- ↑ NMDA receptor binding
- neuronal hyperexcitability
- ↑ dendrite br/spine density
- synaptogenesis
- ↑ cortical thickness

There are also extra-neural processes of interest that affect stroke recovery, e.g., stress, inflammation, metabolism

## The Volume of the Spleen and Its Correlates after Acute Stroke

Nina L. Chiu, BS,\* Brian Kaiser, DO,\* Y Vien Nguyen, DO,†  
Susan Welbourne, BSN, RN,‡ Chandana Lall, MD,† and Steven C. Cramer, MD\*§

# Stroke recovery at the bedside



Change in Fugl-Meyer scale over time after stroke

# A Standardized Approach to Performing the Action Research Arm Test

Nuray Yozbatiran, PT, PhD, Lucy Der-Yeghiaian, MA, OTR/L, and Steven C. Cramer, MD

Yozbatiran et al. Neurorehabil Neural Repair. 2008; 22:78-90.

# A Standardized Approach to Performing the Action Research Arm Test

Nuray Yozbatiran, PT, PhD, Lucy Der-Yeghiaian, MA, OTR/L, and Steven C. Cramer, MD

Yozbatiran et al. *Neurorehabil Neural Repair*. 2008; 22:78-90.

## **A Standardized Approach to the Fugl-Meyer Assessment and Its Implications for Clinical Trials**

**Jill See, MPT<sup>1</sup>, Lucy Dodakian, MA<sup>1</sup>, Cathy Chou, MPT<sup>1</sup>,  
Vicky Chan, MSPT<sup>1</sup>, Alison McKenzie, PhD<sup>2</sup>,  
David J. Reinkensmeyer, PhD<sup>1</sup> and Steven C. Cramer, MD<sup>1</sup>**

Neurorehabilitation and  
Neural Repair

27(8) 732-741

© The Author(s) 2013

Reprints and permissions:

[sagepub.com/journalsPermissions.nav](http://sagepub.com/journalsPermissions.nav)

DOI: 10.1177/1545968313491000



[nnr.sagepub.com](http://nnr.sagepub.com)



See et al. *Neurorehabil Neural Repair*. 2013; 27:732-741.

# A standardized approach to measuring corticospinal tract injury in a clinical study




---



- Corticospinal tract (M1)--uninjured
- Corticospinal tract (M1)--injured by stroke
- Stroke

Measuring extent of corticospinal tract injury to stratify patients

# A standardized approach to measuring corticospinal tract injury in a clinical study



Extent of corticospinal tract injured predicts treatment response

This measure is a better predictor than infarct volume, baseline behavioral status, or demographic measures (n = 23)

# A standardized approach to measuring neurophysiology in a clinical study

---

Malcolm et al., J Clin Trials 2014, 4:6  
<http://dx.doi.org/10.4172/2167-0870.1000199>



**Clinical Trials**

**Protocol**

**Open Access**

Methods for an International Randomized Clinical Trial to Investigate the Effect of Gsk249320 on Motor Cortex Neurophysiology using Transcranial Magnetic Stimulation in Survivors of Stroke

**Matt P. Malcolm<sup>1\*</sup>, Lori Enney<sup>2</sup> and Steven C Cramer<sup>3</sup>**

Malcolm et al, J Clin Trials; 2014



Genetic variation

Measures of neural plasticity

Studies of genetic polymorphisms related to stroke recovery

REVIEW



## The influence of genetic factors on brain plasticity and recovery after neural injury

---

*Kristin M. Pearson-Fuhrhop<sup>a</sup>, Erin Burke<sup>a</sup>, and Steven C. Cramer<sup>a,b</sup>*

---

**Curr Opin Neurol 2012, 25:682-688**

Transl Stroke Res. 2016 Apr 25. [Epub ahead of print]

## **Spontaneous and Therapeutic-Induced Mechanisms of Functional Recovery After Stroke.**

Cassidy JM<sup>1</sup>, Cramer SC<sup>2,3,4,5</sup>.

# Why would clinicians study genetics?

---

Clinicians might study genetics in order to better

- Inform therapeutic decision-making, e.g., Rx choice or Rx dose
- Understand biology and pathogenesis of disease
- Estimate individual risk, prognosis, tendencies
- Stratify enrollees in a clinical trial

# Why would clinicians study genetics?

---

Clinicians might study genetics in order to better

- Inform therapeutic decision-making, e.g., Rx choice or Rx dose
- Understand biology and pathogenesis of disease
- Estimate individual risk, prognosis, tendencies
- Stratify enrollees in a clinical trial

BDNF val<sup>66</sup>met SNP:

an endophenotype of brain function and spontaneous stroke recovery

ApoE4 polymorphism:

Dopamine polygene score:

predicts motor learning, mood, impulsiveness, response to L-Dopa

# Genetics and therapeutic decision-making

---

Persons taking clopidogrel (Plavix) who have CYP2C19 loss-of-function alleles have a higher rate of cardiovascular events compared to those who do not.

Shuldiner et al, JAMA. 2009; 302:849-858

Mega et al, N Engl J Med. 2009; 360:354–362.

# Endophenotype

---

Endophenotype: a measurement (behavioral, imaging, biochemical, etc) linked to a genotype that is useful for distinguishing biological subgroups that look the same clinically.

# Endophenotype

---

Endophenotype: a measurement (behavioral, imaging, biochemical, etc) linked to a genotype that is useful for distinguishing biological subgroups that look the same clinically.

An endophenotype is a component of a complex phenotype that is more directly related to the underlying genotype.



# Endophenotype

---

Endophenotype: a measurement (behavioral, imaging, biochemical, etc) linked to a genotype that is useful for distinguishing biological subgroups that look the same clinically.

An endophenotype is a component of a complex phenotype that is more directly related to the underlying genotype.

Examples: OCD symptoms in certain autism spectrum disorder subgroups; or premotor cortex activation in certain Parkinson's-related genotypes.

# BDNF Val<sup>66</sup>Met Polymorphism Is Related to Motor System Function After Stroke


Dae Yul Kim, Erin B. Quinlan, Robert Gramer, Steven C. Cramer

42 patients with chronic stroke received arm motor robot therapy

Kim et al, Phys Therapy, 2016


# BDNF Val<sup>66</sup>Met Polymorphism Is Related to Motor System Function After Stroke

Dae Yul Kim, Erin B. Quinlan, Robert Gramer, Steven C. Cramer



42 patients with chronic stroke received arm motor robot therapy


Kim et al, Phys Therapy, 2016



Motor cortex activation varied significantly per BDNF genotype.

Same result as was seen in our prior study of healthy controls (McHughen et al, Cerebral Cortex 2010; 20:1254-1262)

Kim et al, Phys Therapy, 2016



Motor cortex activation varied significantly per BDNF genotype.


But: differences in cortical function not related to baseline FM or to change in FM with therapy (wrong motor task during fMRI?)

Kim et al, Phys Therapy, 2016

## Genotype predicts gains in a clinical trial

Among 241 subjects in the GAIN trials

% subjects with min/no disability (*modified Rankin Scale score 0-1*)  
was lower when the ApoE4 genotype present (\* $p = 0.01$ )




Cramer and Procaccio, Eur J Neurol; 2012

## Genotype predicts gains in a clinical trial

Among 241 subjects in the GAIN trials

% subjects with min/no disability (*modified Rankin Scale score 0-1*) was lower when the ApoE4 genotype present (\* $p = 0.01$ )


Getting iv tPA instead of placebo: ARR = 13%



NINDS tPA trial; NEJM, 1995

% subjects with mRS 0-1 at 3 months post-stroke

Getting ApoE4 (-) instead of ApoE4 (+): ARR = 17%



Cramer and Procaccio, Eur J Neurol; 2012

## Polygene score

---

Most genetic effects have RR in range of 1.1-1.4, effect of any single gene generally small--ApoE is a major exception



## Polygene score

---

Most genetic effects have RR in range of 1.1-1.4, effect of any single gene generally small--ApoE is a major exception

Thus interest in combining the effect of many genes in polygenic models or panels...that assigns points for the presence of various risk alleles and calculates an overall risk of disease

## Polygene score

---

Most genetic effects have RR in range of 1.1-1.4, effect of any single gene generally small--ApoE is a major exception

Thus interest in combining the effect of many genes in polygenic models or panels...that assigns points for the presence of various risk alleles and calculates an overall risk of disease

For example, in a study of 5 SNPs associated with prostate cancer, the investigators expressed the risk of disease associated with the increasing presence of risk alleles:

they found an OR of 1.6 with risk allele at 1 SNP and up to 4.5 with risk alleles at 4 SNPs

## Dopamine gene score

---

Constructed a gene score based on the genotype of 5 biologically active polymorphisms related to dopamine

## Dopamine gene score

---

Constructed a gene score based on the genotype of 5 biologically active polymorphisms related to dopamine

Hypothesized subjects with lower dopamine neurotransmission would have

- less learning
- greater boost in learning with L-Dopa
- more depression
- poorer impulse control, greater improvement with Ropinirole

## Dopamine gene score

---

Constructed a gene score based on the genotype of 5 biologically active polymorphisms related to dopamine

Hypothesized subjects with lower dopamine neurotransmission would have

- less learning
- greater boost in learning with L-Dopa
- more depression
- poorer impulse control, greater improvement with Ropinirole

# Genetic Variation in the Human Brain Dopamine System Influences Motor Learning and Its Modulation by L-Dopa


**Kristin M. Pearson-Fuhrhop<sup>1</sup>, Brian Minton<sup>1</sup>, Daniel Acevedo<sup>1</sup>, Babak Shahbaba<sup>2</sup>, Steven C. Cramer<sup>1,3\*</sup>**


<sup>1</sup> Department of Anatomy & Neurobiology, University of California Irvine, Irvine, California, United States of America, <sup>2</sup> Department of Statistics, University of California Irvine, Irvine, California, United States of America, <sup>3</sup> Department of Neurology, University of California Irvine, Irvine, California, United States of America

# Genetic Variation in the Human Brain Dopamine System Influences Motor Learning and Its Modulation by L-Dopa

Kristin M. Pearson-Fuhrhop<sup>1</sup>, Brian Minton<sup>1</sup>, Daniel Acevedo<sup>1</sup>, Babak Shahbaba<sup>2</sup>, Steven C. Cramer<sup>1,3\*</sup>

<sup>1</sup>Department of Anatomy & Neurobiology, University of California Irvine, Irvine, California, United States of America, <sup>2</sup>Department of Statistics, University of California Irvine, Irvine, California, United States of America, <sup>3</sup>Department of Neurology, University of California Irvine, Irvine, California, United States of America







Constructed a gene score based on the genotype of 5 biologically active polymorphisms related to dopamine

Hypothesized subjects with lower dopamine neurotransmission would have

- less learning

- greater boost in learning with L-Dopa

- more depression

- poorer impulse control, greater improvement with Ropinirole

# Dopamine gene score

---


OPEN ACCESS Freely available online



## Dopamine Genetic Risk Score Predicts Depressive Symptoms in Healthy Adults and Adults with Depression

Kristin M. Pearson-Fuhrhop<sup>1</sup>✉, Erin C. Dunn<sup>2,3,4</sup>✉, Sarah Mortero<sup>1</sup>, William J. Devan<sup>2</sup>, Guido J. Falcone<sup>2</sup>, Phil Lee<sup>2,3,4</sup>, Avram J. Holmes<sup>3,5</sup>, Marisa O. Hollinshead<sup>6</sup>, Joshua L. Roffman<sup>3</sup>, Jordan W. Smoller<sup>2,3,4</sup>, Jonathan Rosand<sup>2,7,8</sup>, Steven C. Cramer<sup>1,9\*</sup>

## Dopamine gene score and depression



Lower dopamine gene scores, i.e. lower dopamine neurotransmission, associated with greater depression scores.

Constructed a gene score based on the genotype of 5 biologically active polymorphisms related to dopamine

Hypothesized subjects with lower dopamine neurotransmission would have

- less learning

- greater boost in learning with L-Dopa

- more depression

- poorer impulse control, greater improvement with Ropinirole

# **Dopamine Gene Profiling to Predict Impulse Control and Effects of Dopamine Agonist Ropinirole**

**Hayley J. MacDonald<sup>1</sup>, Cathy M. Stinear<sup>1</sup>, April Ren<sup>1</sup>, James P. Coxon<sup>2</sup>, Justin Kao<sup>3</sup>, Lorraine Macdonald<sup>3</sup>, Barry Snow<sup>3</sup>, Steven C. Cramer<sup>4</sup>, and Winston D. Byblow<sup>1</sup>**

# Dopamine Gene Profiling to Predict Impulse Control and Effects of Dopamine Agonist Ropinirole

Hayley J. MacDonald<sup>1</sup>, Cathy M. Stinear<sup>1</sup>, April Ren<sup>1</sup>, James P. Coxon<sup>2</sup>, Justin Kao<sup>3</sup>, Lorraine Macdonald<sup>3</sup>, Barry Snow<sup>3</sup>, Steven C. Cramer<sup>4</sup>, and Winston D. Byblow<sup>1</sup>

On placebo: lower dopamine gene scores (lower dopamine neurotransmission) associated with poorer impulse control.

On the dopamine agonist Ropinirole: lower dopamine gene scores showed improved response inhibition, while higher gene scores with trend towards worsened response inhibition.

## Moving forward

---

On the one hand, large consortia, big questions, big data.

- Always with precise definitions and measures of phenotype

On the other hand, continue targeted studies of candidate genes.

- Esp those with highest therapeutic implications

- Need mechanistic insights, biomarkers that capture repair events of interest to optimize hypothesis testing

“Genetic variation, stress, and functional outcomes  
after stroke rehabilitation”

R01-NR015591

[stroke@uci.edu](mailto:stroke@uci.edu)



Genetic variation

Measures of neural plasticity

Studies of genetic polymorphisms related to stroke recovery

# Genetics And Neural Plasticity After Stroke

Steven C. Cramer, MD

**Professor, Depts. Neurology, Anatomy & Neurobiology, and PM&R  
Clinical Director, Sue & Bill Gross Stem Cell Research Center  
Associate Director, Institute for Clinical & Translational Science**

**University of California, Irvine**